For Sale: Repros Suffers An FDA Clinical Hold And Potential NASDAQ Delisting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Repros to determine whether a lower dose of Proellex will lessen liver toxicity risks, but the company is strapped for cash.